tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Latest News

Plandaí Biotechnology, Inc. New Products to Hit the Market with Higher Absorption Rate

Plandaí Biotechnology, Inc. New Products to Hit the Market with Higher Absorption Rate

Written by ι Stock Market Media Group Staff — May 14, 2013

In a series of articles Stock Market Media Group, a research and content development investment relations firm, will lay out Plandaí Biotechnology, Inc.’s (OTCQB: PLPL) three new products all being individually labeled and branded under the Phytofare™ name.  In addition to the products, the patented extraction process the company will use to bring customers its healthy lineup of extracts will also be highlighted.  This installment will focus on the first of the three, highly bioavailable extracts – Phytofare™ Catechin Extract.

 Phytofare™ Catechin Extract (“PCE”) is a natural flavonoid rich in phenols and antioxidants.  Catechins are chemical compounds essential to boosting the immune system, lowering cholesterol, fighting obesity, and aiding in the prevention of cancers, malaria, and many other parasitic and viral infections.

Phytofare™ PCE is a 65 percent polyphenol extract containing 85-88 percent catechins through the release of the active and stable immature catechin precursors from the green tea leaf.  Phytonutrients, particularly catechins derived from green tea and its components, have been thoroughly researched (over 200 published scientific papers) and shown to have anti-viral and anti-inflammatory properties.

Most green tea extracts are made from dried unfermented tea leaf – meaning that the antioxidants have been compromised in stability and activity.  However, Phytofare™ PCE is recovered from live plant material, retaining the catechins in an active and stable form.

The Technology Behind the Science

Plandaí Biotechnology will bring to the market a scientifically improved, more bioavailable line of products.  To accomplish this, Plandaí will put on its lab coats and employ a patented extraction process that allows this biotech to beat its competition.  This process begins with the first product the company will bring to market, Phytofare™ Catechin Extract.   Using its proprietary hydrodynamic sheering process, live plant-materials are converted at the molecular level during extraction into a nano-particle structure that mimics that found in human tissues.  So, where most botanical products have less than 10% absorption, Plandaí dramatically enhances the absorption.  According to documented research, Phytofare™ is clinically proven to have far superior absorption.  Higher bioavailability translates into the ability for users to receive a clinical dose with lower quantities.

The top pharmaceutical grade botanical extracts report 80-85% purity through blending and formulation; however, Phytofare™ extracts are naturally 95-98% pure.  This is a huge advantage and allows Plandaí to deliver exceptional purity, combined with exponentially enhanced bioavailability, resulting in a family of botanicals that yield unparalleled results. 

This difference is important to the market because bioavailability is the key to any drug or supplement’s effectiveness.  By definition, when a medication is administered intravenously, its bioavailability is 100%.  When a medication is administered in any other way, orally for instance, its bioavailability generally decreases due to incomplete absorption and may vary from patient to patient.  Bioavailability can be defined as a measurement of the amount of any compound which is absorbed into the bloodstream.  Each year billions are wasted on wellness products that are poorly absorbed.

Plandaí’s dramatically improved bioavailability is a huge win for the user of the company’s products.  Bioavailability in human tissue is enhanced by several methods, all of which focus on improving the molecules’ ability to cross the cellular membrane.  Generally, there are two ways this is accomplished:

—  Decrease the size of the molecule.  The smaller the size, the more easily it can pass through cell walls.

—  Change the properties of the molecules so that they mimic that of human tissues and can, in turn, pass through cellular membranes unhindered.

Plandaí’s proprietary processing and extraction technologies have been shown to increase the bioavailability of phytonutrients and antioxidants by addressing both of these bioavailability advantages. 

The company’s CEO, Roger Duffield, offers a better understanding of the science the company uses with its process that should excite anyone who is interested in science and interested in biotechnology firms that produce exciting products that can make our lives better: 

“A high percentage of drug compounds are synthesized analogs of plant molecules. While botanical material can have tremendous curative properties, it generally has poor bioavailability—or low absorption in human tissues. This is because human tissues have a different molecular structure than plant matter.  A synthetic drug tries to recreate the beneficial elements using a molecule that has greater bioavailability.  Unfortunately, these synthetics often have adverse side effects and, over time, can result in drug-resistant strains of the disease.

 Our patented technology allows us to take specific types of live plant material and unzip the molecules, releasing all of the phytonutrients, and then rearrange the isomeric properties of the molecule so that it mimics the 50/50 ratio commonly found in human tissues.  Simultaneously, we’re able to take out any undesirable elements and reduce the particles to nano-size. 

What this means is that we are able to tailor design the living molecule to maximize the phytonutrient properties and absorption.  So, where most phytonutrients are poorly absorbed in humans, often less than 10%, our products are more fully absorbed. 

The key for us is using live plant materials.  From the moment of harvest, we maintain the material at an optimal temperature and then begin the extraction process within the hour.  This ensures that we are releasing and capturing live anti-oxidants, resulting in a product that is 100% pure bioactive. 

We believe that this technology is the foundation for creating a whole new family of drugs that can treat a multitude of diseases and conditions, safely and affordably using naturally-derived extracts.”

In addition, Plandaí’s unique extraction process allows the systematic removal of any undesirable phytonutrient, like caffeine for instance, resulting in a product that is significantly more pure and concentrated than competing botanicals.

The benefit to those using Plandaí’s products is that with higher bioavailability or absorption rate, a smaller dose is needed, and this allows the company to remain extremely competitive in the market.

Imagine finally buying a product that can benefit you six to eight times more than what is currently on the market.  This is what Plandaí’s highly bioavailable extracts will offer the market. 

Plandaí Biotechnology to Enter the Pharmaceutical Market

One week ago Plandaí Biotechnology announced it had formed Phyto Pharmacare, a subsidiary that will oversee all aspects of developing and marketing Phytofare™ extracts for pharmaceutical and drug applications.  It will operate with its top priority being the commencement of human clinical trials of Phytofare™ Catechin Extract as an anti-malarial drug target.  With upwards of two million deaths every year from malaria infections, this disease has a crippling economic and social cost.

Once approved by the FDA for treating malaria, Phyto Pharmacare will be able to provide a clinical dose of Phytofare™ to at-risk individuals for a fraction of the current vaccine costs.  This could provide Plandaí Biotechnology with a low cost solution to immunizing the entire population of sub-Sahara Africa against malaria, viruses, and parasites, as well as a defense mechanism for the immune system.

Plandaí says Phytofare™ will ideally be marketed to government agencies as an anti-malarial drug following successful in-vivo testing and FDA approval.